Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) shares saw an uptick in trading volume on Wednesday . 2,847 shares changed hands during trading, an increase of 75% from the previous session’s volume of 1,631 shares.The stock last traded at $9.50 and had previously closed at $9.3550.

Bavarian Nordic Trading Down 1.0%

The firm has a 50-day simple moving average of $10.06 and a two-hundred day simple moving average of $10.66. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of 10.65 and a beta of 1.34.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its earnings results on Thursday, March 12th. The company reported ($0.20) EPS for the quarter. The company had revenue of $226.16 million during the quarter. Bavarian Nordic had a return on equity of 11.44% and a net margin of 22.20%. Equities research analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.